AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2082483 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg aspirin combined with 400 mg dipyridamole
Number of subjects: 249
Study 2082483 — intervention group
Group type: COMPARATOR
Intervention: Standard anticoagulant therapy
Number of subjects: 249
Study 34814 — intervention group
Group type: EXPERIMENTAL
Intervention: Floctafenine
Number of subjects: 0
Study 34814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30251330 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg tadalafil
Number of subjects: 75
Study 30251330 — intervention group
Group type: COMPARATOR
Intervention: 5 mg solifenacin
Number of subjects: 75
Study 27871828 — intervention group
Group type: EXPERIMENTAL
Intervention: Voiding during catheterization
Number of subjects: 96
Study 26438038 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12 % I‐C nasal spray, four times daily for four to ten days
Number of subjects: 200
Study 26438038 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray (NaCl 0.5 %), four times daily for four to ten days
Number of subjects: 200
Study 26438038 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12 % I‐C nasal spray
Number of subjects: 200
Study 26438038 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray (NaCl 0.5 %)
Number of subjects: 200
Study 24279305 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline (200 mg/day orally) added to regular antipsychotic medications for 12 weeks
Number of subjects: 150
Study 24279305 — intervention group
Group type: COMPARATOR
Intervention: Placebo (inactive compound identical in appearance to minocycline)
Number of subjects: 150
Study 24279305 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline (200 mg/day orally)
Number of subjects: 150
Study 22081616 — intervention group
Group type: EXPERIMENTAL
Intervention: L. barbarum (120 ml)
Number of subjects: 29
Study 22081616 — intervention group
Group type: EXPERIMENTAL
Intervention: L. barbarum (120 ml daily for 14 days)
Number of subjects: 29
Study 22081616 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 19822837 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) and cognitive behavioral skills training (CBST) counseling intervention
Number of subjects: 1058
Study 17542347 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg
Number of subjects: 60
Study 17542347 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 60
Study 15880608 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (peginterferon and lamivudine)
Number of subjects: 95
Study 15880608 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine monotherapy
Number of subjects: 95
Study 14624818 — intervention group
Group type: EXPERIMENTAL
Intervention: Group comprehensive cognitive behavioral therapy (CCBT)
Number of subjects: 0
Study 14624818 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (FLU)
Number of subjects: 0
Study 14624818 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 0
Study 14624818 — intervention group
Group type: COMPARATOR
Intervention: Combination of FLU and PLA
Number of subjects: 0
Study 10477209 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 19
Study 10477209 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 8723584 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa (100 IU/kg or 300 IU/kg) administered daily by subcutaneous injection, commencing 10 days preoperatively and continuing until day 4 postoperatively (15 doses in total)
Number of subjects: 200
Study 8723584 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa (100 IU/kg)
Number of subjects: 200
Study 8723584 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa (600 IU/kg)
Number of subjects: 200
Study 8723584 — intervention group
Group type: COMPARATOR
Intervention: Epoetin alfa (any regimen)
Number of subjects: 200
Study 2058823 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2.5 mg/kg i.v. induction and 3-5 mg/kg per hour i.v. maintenance
Number of subjects: 30
Study 2058823 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental 5 mg/kg i.v. induction and isoflurane 0.4-0.8 vol.% maintenance
Number of subjects: 30
Study 2058823 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate 0.2 mg/kg i.v. induction and flunitrazepam 0.005-0.01 mg/kg i.v. and fentanyl 0.0025-0.005 mg/kg i.v. bolus injections every 20-30 min maintenance
Number of subjects: 30
Study 2058823 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam/fentanyl maintenance
Number of subjects: 30
Study 2058823 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane and propofol maintenance
Number of subjects: 30
Study 6286118 — intervention group
Group type: EXPERIMENTAL
Intervention: PIVN-associated chemotherapy (adriamycin, vincristine, VP16‐213 and cyclophosphamide) with 1550 kcal/day including 10% glucose, 20% lipids, and amino acids.
Number of subjects: 19
Study 6286118 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy control group (adriamycin, vincristine, VP16‐213 and cyclophosphamide) without PIVN.
Number of subjects: 19
Study 6286118 — intervention group
Group type: EXPERIMENTAL
Intervention: PIVN-associated chemotherapy
Number of subjects: 19
Study 6286118 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy control group
Number of subjects: 19
Study 6286118 — intervention group
Group type: COMPARATOR
Intervention: PIVN-associated chemotherapy and chemotherapy control group
Number of subjects: 19
Study 31495192 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping
Number of subjects: 30
Study 31495192 — intervention group
Group type: COMPARATOR
Intervention: Compression garments
Number of subjects: 30
Study 28728580 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricted activity for 30 days post-surgery
Number of subjects: 210
Study 28728580 — intervention group
Group type: COMPARATOR
Intervention: Unrestricted activity for 30 days post-surgery
Number of subjects: 210
Study 26863464 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally and linguistically adapted physical activity print intervention for 6 months
Number of subjects: 196
Study 26863464 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 196
Study 23657665 — intervention group
Group type: EXPERIMENTAL
Intervention: nCPAP with humidification
Number of subjects: 31
Study 23657665 — intervention group
Group type: COMPARATOR
Intervention: nCPAP without humidification
Number of subjects: 31
Study 23657665 — intervention group
Group type: EXPERIMENTAL
Intervention: nCPAP with and without humidification
Number of subjects: 31
Study 22966839 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration therapy (WBV) for 2 weeks, six 15-min sessions, 2 mm amplitude, 12 Hz frequency
Number of subjects: 27
Study 22966839 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 27
Study 22966839 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration therapy (WBV)
Number of subjects: 27
Study 19524285 — intervention group
Group type: EXPERIMENTAL
Intervention: c-MYC amplification (defined as > or =2 copies c-MYC/CEP8)
Number of subjects: 97
Study 19524285 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysomy 8
Number of subjects: 97
Study 17470020 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen sodium (275 mg daily for 6 weeks)
Number of subjects: 34
Study 17470020 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 15240605 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone (4.1 mg/patch, twice a week; estimated delivery rate, 150 microg/d)
Number of subjects: 31
Study 15240605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 12421172 — intervention group
Group type: EXPERIMENTAL
Intervention: Joel-Cohen incision
Number of subjects: 366
Study 12421172 — intervention group
Group type: COMPARATOR
Intervention: Pfannenstiel incision
Number of subjects: 366
Study 9615369 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulant chemotherapy
Number of subjects: 53
Study 9615369 — intervention group
Group type: EXPERIMENTAL
Intervention: Children younger than 10 years old
Number of subjects: 53
Study 9615369 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients older than 17 years
Number of subjects: 53
Study 8583218 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole 800 mg/day for 8 days
Number of subjects: 53
Study 8583218 — intervention group
Group type: COMPARATOR
Intervention: Albendazole 800 mg/day for 15 days
Number of subjects: 53
Study 8583218 — intervention group
Group type: COMPARATOR
Intervention: Albendazole 800 mg/day for 30 days
Number of subjects: 53
Study 8583218 — intervention group
Group type: COMPARATOR
Intervention: High dose steroids
Number of subjects: 53
Study 8583218 — intervention group
Group type: COMPARATOR
Intervention: Albendazole
Number of subjects: 53
Study 2677294 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (0.2 mg/kg intravenously at 6 hours of age and 0.1 mg/kg at 18 and 30 hours)
Number of subjects: 141
Study 2677294 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study 641180 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral Right ECT (UR)
Number of subjects: 0
Study 641180 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral Left ECT (UL)
Number of subjects: 0
Study 641180 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral ECT (B)
Number of subjects: 0
Study 641180 — intervention group
Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 0
Study 31153148 — intervention group
Group type: EXPERIMENTAL
Intervention: Gross-total resection
Number of subjects: 12931
Study 31153148 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy after subtotal resection
Number of subjects: 12931
Study 31153148 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy after gross-total resection
Number of subjects: 12931
Study 31153148 — intervention group
Group type: COMPARATOR
Intervention: Gross-total resection plus radiotherapy
Number of subjects: 12931
Study 31153148 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant radiation after subtotal resection
Number of subjects: 12931
Study 28062315 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-step technique
Number of subjects: 32
Study 28062315 — intervention group
Group type: COMPARATOR
Intervention: WHO six-step technique
Number of subjects: 32
Study 26238866 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple Sclerosis Impact Profile (MSIP)
Number of subjects: 0
Study 26238866 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple Sclerosis Quality of Life-54 items (MSQoL-54)
Number of subjects: 0
Study 26238866 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Fatigue Impact Scale-5 items (MFIS-5)
Number of subjects: 0
Study 26238866 — intervention group
Group type: EXPERIMENTAL
Intervention: Leeds Multiple Sclerosis Quality of Life-8 items (LMSQoL)
Number of subjects: 0
Study 26238866 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication and Adherence Inventory
Number of subjects: 0
Study 26238866 — intervention group
Group type: EXPERIMENTAL
Intervention: Expanded Disability Status Scale (EDSS)
Number of subjects: 0
Study 22913797 — intervention group
Group type: COMPARATOR
Intervention: Myopic group (n = 58)
Number of subjects: 154
Study 22913797 — intervention group
Group type: COMPARATOR
Intervention: Hyperopic group (n = 62)
Number of subjects: 154
Study 22913797 — intervention group
Group type: EXPERIMENTAL
Intervention: Emmetropic control group (n = 34)
Number of subjects: 154
Study 19683703 — intervention group
Group type: EXPERIMENTAL
Intervention: Well-Being intervention
Number of subjects: 227
Study 19683703 — intervention group
Group type: COMPARATOR
Intervention: Attention-placebo
Number of subjects: 227
Study 16505505 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine 10 units/day
Number of subjects: 217
Study 16505505 — intervention group
Group type: COMPARATOR
Intervention: Rosiglitazone 4 mg/day
Number of subjects: 217
Study 15497664 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor 500 mg capsules (Losefar 500 mg Capsules)
Number of subjects: 2
Study 15497664 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor 250 mg/5 mL suspension (Losefar 250 mg/5 mL Granules oral suspension)
Number of subjects: 2
Study 15497664 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor (both formulations)
Number of subjects: 2
Study 11266032 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral vitamin B12 (3 injections of 1 mg at 4-week intervals)
Number of subjects: 14
Study 11266032 — intervention group
Group type: COMPARATOR
Intervention: Control group (high doses of folic acid and replacement-dose oral vitamin B12)
Number of subjects: 14
Study 9135187 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceleromyography (TOF‐Guard)
Number of subjects: 15
Study 9135187 — intervention group
Group type: COMPARATOR
Intervention: Mechanomyography (Grass FT03)
Number of subjects: 15
Study 9135187 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceleromygraphy
Number of subjects: 15
Study 8044004 — intervention group
Group type: COMPARATOR
Intervention: Controlled trials in JITWM
Number of subjects: 314
Study 8044004 — intervention group
Group type: COMPARATOR
Intervention: Controlled trials in JTCM
Number of subjects: 314
Study 8044004 — intervention group
Group type: COMPARATOR
Intervention: Controlled trials in JTM
Number of subjects: 314
Study 8044004 — intervention group
Group type: COMPARATOR
Intervention: Randomized trials in JITWM
Number of subjects: 314
Study 8044004 — intervention group
Group type: COMPARATOR
Intervention: Randomized trials in JTCM
Number of subjects: 314
Study 8044004 — intervention group
Group type: COMPARATOR
Intervention: Randomized trials in JTM
Number of subjects: 314
Study 8044004 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality ranking of clinical trials
Number of subjects: 314
Study 3692076 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical analysis of ST-T isoarea maps using body surface maps (BSM) recorded from 140 thoracic leads.
Number of subjects: 38
Study 3692076 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning set analysis with 17 pts without VT and 9 pts with VT.
Number of subjects: 38
Study 3692076 — intervention group
Group type: EXPERIMENTAL
Intervention: Test set analysis with 8 pts without VT and 4 pts with VT.
Number of subjects: 38
Study 29303475 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training intervention (ACTIVE framework)
Number of subjects: 2802
Study 27378326 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 8
Study 27378326 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 26547682 — intervention group
Group type: EXPERIMENTAL
Intervention: Function Focused Care Intervention
Number of subjects: 25
Study 22965772 — intervention group
Group type: COMPARATOR
Intervention: RT-only treatment group (11 solitary and 3 multiple tumors)
Number of subjects: 28
Study 22965772 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment group (10 solitary and 4 multiple tumors, neo-adjuvant CTX followed by response-adapted RT)
Number of subjects: 28
Study 22965772 — intervention group
Group type: COMPARATOR
Intervention: RT-only treatment group
Number of subjects: 28
Study 22965772 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment group
Number of subjects: 28
Study 20850812 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (0.025 mg/kg nightly for 1 week, then increased to 2 divided doses)
Number of subjects: 62
Study 20850812 — intervention group
Group type: COMPARATOR
Intervention: Placebo (nightly for 1 week, then increased to 2 divided doses)
Number of subjects: 62
Study 20850812 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 62
Study 18413501 — intervention group
Group type: EXPERIMENTAL
Intervention: OPCABG
Number of subjects: 60
Study 18413501 — intervention group
Group type: COMPARATOR
Intervention: ONCABG
Number of subjects: 60
Study 16753082 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported physical functioning
Number of subjects: 127
Study 16753082 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 127
Study 16753082 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower levels of physical functioning
Number of subjects: 127
Study 16753082 — intervention group
Group type: EXPERIMENTAL
Intervention: Weaker psychological attributions
Number of subjects: 127
Study 16753082 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 127
Study 16753082 — intervention group
Group type: EXPERIMENTAL
Intervention: Work disability benefits
Number of subjects: 127
Study 12610251 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational computer program accessible via Internet or touch-tone telephone
Number of subjects: 786
Study 12610251 — intervention group
Group type: COMPARATOR
Intervention: Information-only control condition
Number of subjects: 786
Study 12043712 — intervention group
Group type: EXPERIMENTAL
Intervention: Four- or eight-week intervention aimed at reducing sexual risk
Number of subjects: 360
Study 12043712 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 360
Study 9798830 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment plus whirlpool (Group B)
Number of subjects: 42
Study 9798830 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment only (Group A)
Number of subjects: 42
Study 8033762 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased methadone dose (50-80 mg)
Number of subjects: 5
Study 8033762 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased methadone dose (80-50 mg)
Number of subjects: 5
Study 8033762 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring
Number of subjects: 5
Study 8033762 — intervention group
Group type: EXPERIMENTAL
Intervention: Expired air carbon monoxide (CO) measurement
Number of subjects: 5
Study 2500273 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Intraglobin F (300 mg/kg body weight every 4 weeks)
Number of subjects: 12
Study 2500273 — intervention group
Group type: COMPARATOR
Intervention: Standard intramuscular injections (25 mg/kg body weight every week after a 4-week loading phase of 50 mg/kg/week)
Number of subjects: 12
Study 2500273 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Intraglobin F (300 mg/kg body weight every 3 weeks after initial treatment)
Number of subjects: 12
Study 2500273 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Intraglobin F
Number of subjects: 12
Study 4881069 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine
Number of subjects: 0
Study 4881069 — intervention group
Group type: EXPERIMENTAL
Intervention: Suramin
Number of subjects: 0
Study 4881069 — intervention group
Group type: EXPERIMENTAL
Intervention: Mel W
Number of subjects: 0
Study 30583852 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-Child Interaction Therapy-Emotion Development (PCIT-ED)
Number of subjects: 118
Study 30583852 — intervention group
Group type: COMPARATOR
Intervention: Waitlist (WL) control
Number of subjects: 118
Study 28160720 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 41
Study 28160720 — intervention group
Group type: COMPARATOR
Intervention: Waitlist (Control)
Number of subjects: 41
Study 24548796 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 10
Study 24548796 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 10
Study 23959084 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity Intervention (PA)
Number of subjects: 176
Study 23959084 — intervention group
Group type: COMPARATOR
Intervention: Control Group (C)
Number of subjects: 176
Study 21327633 — intervention group
Group type: EXPERIMENTAL
Intervention: α‐tocopherol (400 IU per day for entire period of radiotherapy)
Number of subjects: 0
Study 21327633 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (6000 cGY in five fractions per week for a period of six weeks)
Number of subjects: 0
Study 19574612 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant nutrient cocktail
Number of subjects: 19
Study 19574612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 17342169 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 0.2 mg
Number of subjects: 16
Study 17342169 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 400 mg
Number of subjects: 16
Study 17342169 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 17342169 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of clonidine and modafinil
Number of subjects: 16
Study 15538264 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual apomorphine (3 mg)
Number of subjects: 34
Study 15538264 — intervention group
Group type: COMPARATOR
Intervention: Oral sildenafil (50 mg)
Number of subjects: 34
Study 15538264 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 34
Study 11340689 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (64 micrograms)
Number of subjects: 6
Study 11340689 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 11340689 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylometazoline (140 micrograms)
Number of subjects: 6
Study 9481967 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthetic
Number of subjects: 61
Study 9481967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 9481967 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthetic with vibration
Number of subjects: 61
Study 7532319 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenidap 120 mg/day
Number of subjects: 0
Study 3035913 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum (60 mg/m2), doxorubicin (40 mg/m2), and VP-16 (150 mg/m2) (PAV)
Number of subjects: 44
Study 3035913 — intervention group
Group type: COMPARATOR
Intervention: Platinum (60 mg/m2), 4'-epidoxorubicin (50 mg/m2), and VP-16 (150 mg/m2) (PEV)
Number of subjects: 44
Study 31137026 — intervention group
Group type: EXPERIMENTAL
Intervention: 38% silver diamine fluoride (SDF) treatment
Number of subjects: 20
Study 28875511 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended brief intervention for alcohol misuse
Number of subjects: 0